Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julie Parsons

Neurology with Special Qualifications in Child Neurology Aurora, CO Medical Doctor

NPI 1396820031 CMS profile 602199

13123 E 16Th Ave, Aurora, CO 80045

Open in the dashboard

General payments

$177,894

217 records reported · program years 2019–2025

Research payments

$4,753

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,834,880 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Julie Parsons of Aurora, CO is reported in the CMS Open Payments database as having received $177,894 across 217 general payments and $4,753 in research payments paid to them. Separately, studies naming them as principal investigator received $2,834,880 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,387 18
2024 General $39,134 26
2024 Research $1,633 1
2023 General $28,175 22
2022 General $36,885 26
2021 General $11,863 17
2020 General $24,482 52
2020 Research $3,120 1
2019 General $19,967 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Parsons
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Julie Parsons were reported at $17,387. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Julie Parsons Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $19,967 $262 $68–$1,313 $163
2020 $24,482 $188 $46–$1,222 $114
2021 $11,863 $183 $45–$1,356 $132
2022 $36,885 $229 $72–$1,177 $149
2023 $28,175 $269 $93–$1,195 $160
2024 $39,134 $300 $98–$1,428 $164
2025 $17,387 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $53,410 36 payments
  2. AveXis $37,269 117 payments
  3. Genentech USA, Inc. $23,539 18 payments
  4. Ultragenyx Pharmaceutical Inc. $20,173 9 payments
  5. Genzyme Corporation $19,445 6 payments
  6. Novartis Pharmaceuticals Corporation $15,802 11 payments
  7. Pfizer Inc. $5,129 4 payments
  8. PTC Therapeutics, Inc. $1,600 1 payment
  9. Sarepta Therapeutics, Inc. $977 10 payments
  10. Astellas Pharma US Inc $384 2 payments
  11. Other $165 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $100,062 36 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,503 17 payments
  3. Education $22,638 95 payments
  4. Honoraria $14,465 5 payments
  5. Travel and Lodging $13,170 23 payments
  6. Food and Beverage $4,056 41 payments
Products named General payments · program years 2019–2025
  1. SPINRAZA $50,088 33 payments
  2. ZOLGENSMA Gene Therapy $32,574 112 payments
  3. Evrysdi $23,680 19 payments
  4. ZOLGENSMA Neurology $15,802 11 payments
  5. Skyclarys $135 1 payment
  6. QALSODY $135 1 payment
  7. AGAMREE $13 1 payment
  8. KYPHON Balloon Kyphoplasty $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biogen, Inc. $3,120 1 payment
  2. AveXis $1,633 1 payment

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record